FATE – Fate Therapeutics, Inc.
Fate Therapeutics, Inc.FATE
$0.9946Name : Fate Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $114,729,384.00
EPSttm : -1.33
Fate Therapeutics, Inc.
$0.9946
3.17%$0.0306Float Short %
6.23
Margin Of Safety %
Put/Call OI Ratio
0.22
EPS Next Q Diff
0.02
EPS Last/This Y
0.5
EPS This/Next Y
-0.04
Price
0.96
Target Price
4.94
Analyst Recom
2
Performance Q
-19.67
Relative Volume
1.32
Beta
2.38
Ticker: FATE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-20 | FATE | 1.54 | 0.09 | 0.00 | 6461 |
| 2025-10-21 | FATE | 1.53 | 0.08 | 0.31 | 6855 |
| 2025-10-22 | FATE | 1.48 | 0.10 | 0.01 | 7181 |
| 2025-10-23 | FATE | 1.515 | 0.09 | 0.13 | 7313 |
| 2025-10-24 | FATE | 1.645 | 0.09 | 0.05 | 7361 |
| 2025-10-27 | FATE | 1.55 | 0.09 | 0.10 | 7494 |
| 2025-10-28 | FATE | 1.485 | 0.10 | 0.00 | 7668 |
| 2025-10-29 | FATE | 1.34 | 0.10 | 0.08 | 7541 |
| 2025-10-30 | FATE | 1.285 | 0.10 | 0.07 | 7562 |
| 2025-10-31 | FATE | 1.37 | 0.10 | 0.00 | 7564 |
| 2025-11-03 | FATE | 1.255 | 0.10 | 0.48 | 7773 |
| 2025-11-04 | FATE | 1.195 | 0.11 | 0.01 | 7987 |
| 2025-11-05 | FATE | 1.09 | 0.11 | 0.63 | 8101 |
| 2025-11-06 | FATE | 1.035 | 0.11 | 2.73 | 8156 |
| 2025-11-07 | FATE | 1.08 | 0.21 | 0.02 | 9031 |
| 2025-11-10 | FATE | 1.09 | 0.21 | 0.25 | 9083 |
| 2025-11-11 | FATE | 1.115 | 0.21 | 0.00 | 9081 |
| 2025-11-12 | FATE | 1.04 | 0.21 | 1.22 | 9042 |
| 2025-11-13 | FATE | 0.9814 | 0.21 | 0.00 | 9126 |
| 2025-11-14 | FATE | 0.9601 | 0.22 | 0.00 | 9053 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-20 | FATE | 1.54 | 29.9 | - | -1.10 |
| 2025-10-21 | FATE | 1.53 | 29.9 | - | -1.10 |
| 2025-10-22 | FATE | 1.49 | 29.9 | - | -1.10 |
| 2025-10-23 | FATE | 1.52 | 29.9 | - | -1.10 |
| 2025-10-24 | FATE | 1.64 | 29.9 | - | -1.10 |
| 2025-10-27 | FATE | 1.55 | 29.9 | - | -1.10 |
| 2025-10-28 | FATE | 1.49 | 29.9 | - | -1.10 |
| 2025-10-29 | FATE | 1.34 | 29.9 | - | -1.10 |
| 2025-10-30 | FATE | 1.29 | 29.9 | - | -1.10 |
| 2025-10-31 | FATE | 1.35 | 29.6 | - | -1.14 |
| 2025-11-03 | FATE | 1.26 | 29.6 | - | -1.14 |
| 2025-11-04 | FATE | 1.20 | 29.6 | - | -1.14 |
| 2025-11-05 | FATE | 1.09 | 29.6 | - | -1.14 |
| 2025-11-06 | FATE | 1.03 | 29.6 | - | -1.14 |
| 2025-11-07 | FATE | 1.07 | 29.4 | - | -1.14 |
| 2025-11-10 | FATE | 1.09 | 29.5 | - | -1.14 |
| 2025-11-11 | FATE | 1.12 | 29.5 | - | -1.14 |
| 2025-11-12 | FATE | 1.03 | 29.5 | - | -1.14 |
| 2025-11-13 | FATE | 0.98 | 29.5 | - | -1.14 |
| 2025-11-14 | FATE | 0.96 | 42.6 | - | -1.14 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-20 | FATE | -0.40 | -13.08 | 7.30 |
| 2025-10-21 | FATE | -0.40 | -13.08 | 7.30 |
| 2025-10-22 | FATE | -0.40 | -13.08 | 7.30 |
| 2025-10-23 | FATE | -0.40 | -13.08 | 7.30 |
| 2025-10-24 | FATE | -0.40 | -13.08 | 7.30 |
| 2025-10-27 | FATE | -0.40 | -14.14 | 6.89 |
| 2025-10-28 | FATE | -0.40 | -14.14 | 6.88 |
| 2025-10-29 | FATE | -0.41 | -14.14 | 6.88 |
| 2025-10-30 | FATE | -0.41 | -14.14 | 6.88 |
| 2025-10-31 | FATE | -0.41 | -14.14 | 6.88 |
| 2025-11-03 | FATE | -0.41 | -12.99 | 6.88 |
| 2025-11-04 | FATE | -0.41 | -12.99 | 6.88 |
| 2025-11-05 | FATE | -0.41 | -12.99 | 6.88 |
| 2025-11-06 | FATE | -0.41 | -12.99 | 6.88 |
| 2025-11-07 | FATE | -0.41 | -12.99 | 6.88 |
| 2025-11-10 | FATE | -0.41 | -12.83 | 6.88 |
| 2025-11-11 | FATE | -0.41 | -12.83 | 6.88 |
| 2025-11-12 | FATE | -0.41 | -12.83 | 6.23 |
| 2025-11-13 | FATE | -0.41 | -12.83 | 6.23 |
| 2025-11-14 | FATE | -0.41 | -12.83 | 6.23 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.29
Avg. EPS Est. Current Quarter
-0.28
Avg. EPS Est. Next Quarter
-0.27
Insider Transactions
-0.41
Institutional Transactions
-12.83
Beta
2.38
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
13
Growth Score
23
Sentiment Score
12
Actual DrawDown %
99.2
Max Drawdown 5-Year %
-99.4
Target Price
4.94
P/E
Forward P/E
PEG
P/S
15.57
P/B
0.48
P/Free Cash Flow
EPS
-1.32
Average EPS Est. Cur. Y
-1.14
EPS Next Y. (Est.)
-1.17
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2187.11
Relative Volume
1.32
Return on Equity vs Sector %
-92.5
Return on Equity vs Industry %
-77.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
Fate Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading